<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?npg-journal-abbreviation?><?properties open_access?><?DTDIdentifier.IdentifierValue -//NPGSJ//DTD full length article DTD version 7.0 XML//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ajarticle_v7_x.dtd?><?SourceDTD.Version 7.0?><?ConverterInfo.XSLTName naturesa2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Genes Immun</journal-id><journal-id journal-id-type="iso-abbrev">Genes Immun</journal-id><journal-title-group><journal-title>Genes and Immunity</journal-title></journal-title-group><issn pub-type="ppub">1466-4879</issn><issn pub-type="epub">1476-5470</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4895389</article-id><article-id pub-id-type="pii">gene201612</article-id><article-id pub-id-type="doi">10.1038/gene.2016.12</article-id><article-id pub-id-type="pmid">26986782</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Cistromic and genetic evidence that the vitamin D receptor mediates susceptibility to latitude-dependent autoimmune diseases</article-title><alt-title alt-title-type="running">VDR cistrome in myeloid cells</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Booth</surname><given-names>D R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Parnell</surname><given-names>G P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shahijanian</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Coulter</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Schibeci</surname><given-names>S D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Atkins</surname><given-names>A R</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>G J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>R M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Downes</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liddle</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><aff id="aff1"><label>1</label><institution>Centre for Immunology, Westmead Institute for Medical Research, University of Sydney</institution>, Sydney, New South Wales, <country>Australia</country></aff><aff id="aff2"><label>2</label><institution>Gene Expression Laboratory, Salk Institute</institution>, La Jolla, CA, <country>USA</country></aff><aff id="aff3"><label>3</label><institution>Storr Liver Unit, Westmead Institute for Medical Research, University of Sydney</institution>, Sydney, New South Wales, <country>Australia</country></aff><aff id="aff4"><label>4</label><institution>Howard Hughes Medical Institute, Salk Institute</institution>, La Jolla, CA, <country>USA</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label><institution>Westmead Institute for Medical Research, University of Sydney</institution>, 176 Hawkesbury Rd, Westmead, Sydney, New South Wales 2145, <country>Australia</country>. E-mail: <email>david.booth@sydney.edu.au</email></corresp></author-notes><pub-date pub-type="ppub"><month>06</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>17</day><month>03</month><year>2016</year></pub-date><volume>17</volume><issue>4</issue><fpage>213</fpage><lpage>219</lpage><history><date date-type="received"><day>08</day><month>12</month><year>2015</year></date><date date-type="rev-recd"><day>28</day><month>01</month><year>2016</year></date><date date-type="accepted"><day>01</day><month>02</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Macmillan Publishers Limited</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Macmillan Publishers Limited</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><abstract><p>The vitamin D receptor (VDR) is a ligand-activated transcription factor that regulates gene expression in many cell types, including immune cells. It requires binding of 1,25 dihydroxy vitamin D<sub>3</sub> (1,25D3) for activation. Many autoimmune diseases show latitude-dependent prevalence and/or association with vitamin D deficiency, and vitamin D supplementation is commonly used in their clinical management. 1,25D3 is regulated by genes associated with the risk of autoimmune diseases and predominantly expressed in myeloid cells. We determined the VDR cistrome in monocytes and monocyte-derived inflammatory (DC1) and tolerogenic dendritic cells (DC2). VDR motifs were highly overrepresented in ChIP-Seq peaks in stimulated monocyte (40&#x00025;), DC1 (21&#x00025;) and DC2 (47&#x00025;), <italic>P&#x0003c;</italic>E<sup>&#x02212;100</sup> for all. Of the nearly 11&#x02009;000 VDR-binding peaks identified across the genome in DC1s, 1317 were shared with DC2s (91&#x00025; of DC2 sites) and 1579 with monocytes (83&#x00025; of monocyte sites). Latitude-dependent autoimmune disease risk polymorphisms were highly overrepresented within 5&#x02009;kb of the peaks. Several transcription factor recognition motifs were highly overrepresented in the peaks, including those for the autoimmune risk gene, <italic>BATF</italic>. This evidence indicates that VDR regulates hundreds of myeloid cell genes and that the molecular pathways controlled by VDR in these cells are important in maintaining tolerance.</p></abstract></article-meta></front><body><sec><title>Introduction</title><p>Genome-wide association studies have identified hundreds of autoimmune risk genes, many shared across diseases.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref></sup> The challenge now is to use this genetic road map to better define the pathogenesis of the diseases and develop novel effective therapies and clinically useful biomarkers. The prevalence of many autoimmune diseases increases with distance from the equator in genetically similar populations in many countries.<sup><xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref>, <xref ref-type="bibr" rid="bib7">7</xref>, <xref ref-type="bibr" rid="bib8">8</xref>, <xref ref-type="bibr" rid="bib9">9</xref>, <xref ref-type="bibr" rid="bib10">10</xref></sup> These associations have been attributed to reduced exposure to UV radiation, and consequent Vitamin D (Vit D) deficiency. This is supported by evidence of the importance of Vit D in immunomodulation.<sup><xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref>, <xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref>, <xref ref-type="bibr" rid="bib15">15</xref>, <xref ref-type="bibr" rid="bib16">16</xref>, <xref ref-type="bibr" rid="bib17">17</xref></sup></p><p>Several recent lines of unrelated investigation provide further strong support for a key role of Vit D in the pathogenesis of autoimmune disorders. Two of the autoimmune-associated genes, <italic>CYP27B1</italic> and <italic>CYP24A1</italic>, control the availability of the ligand for the endogenous Vit D receptor (VDR), 1,25-dihydroxyvitamin D<sub>3</sub> (1,25D3): <italic>CYP27B1</italic> converts the precursor 25D3 to 1,25D3 and <italic>CYP24A1</italic> enhances catabolism of 1,25D3. These genes (<italic>CYP27B1</italic>/<italic>CYP24A1</italic>/<italic>VDR</italic>), singly or collectively, have been identified as risk factors in multiple autoimmune diseases.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref>, <xref ref-type="bibr" rid="bib21">21</xref>, <xref ref-type="bibr" rid="bib22">22</xref>, <xref ref-type="bibr" rid="bib23">23</xref></sup> Second, Vit D supplementation has been found to be of therapeutic benefit in animal models of autoimmune disease, including in autoimmune encephalomyelitis, collagen-induced arthritis, type 1 diabetes mellitus, inflammatory bowel disease, autoimmune thyroiditis and systemic lupus erythematosus.<sup><xref ref-type="bibr" rid="bib24">24</xref></sup> Further, at a clinical level, higher serum Vit D levels are associated with reduced risk of autoimmune diseases<sup><xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref>, <xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref>, <xref ref-type="bibr" rid="bib15">15</xref>, <xref ref-type="bibr" rid="bib16">16</xref>, <xref ref-type="bibr" rid="bib17">17</xref>, <xref ref-type="bibr" rid="bib25">25</xref></sup> and the function of regulatory T cells (Tregs) in patients has been shown to be proportional to serum 25D3 levels.<sup><xref ref-type="bibr" rid="bib26">26</xref></sup> As a result of these findings, Vit D has been considered a promising target pathway for therapeutic intervention and clinical trials have commenced (ahead of more detailed knowledge of the microenvironment in which Vit D immunomodulation occurs).</p><p>Activation of VDR by 1,25D3 results in the liganded receptor binding to a large number of genes (the VDR cistrome). We propose that a major mechanism by which VDR activation influences autoimmunity is through gene activation in immune cells of myeloid lineage, particularly antigen-presenting dendritic cells (DCs) with consequent activation of tolerizing states in the immune system, especially in DCs.<sup><xref ref-type="bibr" rid="bib27">27</xref>, <xref ref-type="bibr" rid="bib28">28</xref></sup> We base this on several observations. VDR activation induces a tolerogenic phenotype in antigen-presenting cells, including DCs.<sup><xref ref-type="bibr" rid="bib29">29</xref></sup> Within immune cells, <italic>CYP27B1</italic> and <italic>CYP24A1</italic> are predominantly expressed in DCs<sup><xref ref-type="bibr" rid="bib30">30</xref>, <xref ref-type="bibr" rid="bib31">31</xref></sup> (it seems likely T cells need an exogenous source of 1,25D3 since they have limited <italic>CYP27B1</italic> expression). In mouse models of autoimmune disease treatment with antigen-specific or generic tolerogenic DCs is remarkably successful.<sup><xref ref-type="bibr" rid="bib32">32</xref>, <xref ref-type="bibr" rid="bib33">33</xref></sup> This has led to clinical trials in humans, with promising results, especially with autologous DCs.<sup><xref ref-type="bibr" rid="bib34">34</xref></sup> However, a major limitation is that DCs can be quite plastic, so that the choice of manipulation needs to be further informed by experimental data, and reliable quality control measurements of manipulation are needed. Given that the importance of Vit D in inducing and maintaining a tolerogenic DC phenotype is well established,<sup><xref ref-type="bibr" rid="bib28">28</xref>, <xref ref-type="bibr" rid="bib35">35</xref></sup> identification of the molecular basis for this may lead to new tools to manipulate and assess DCs.</p><p>Although the spectrum of genes regulated by VDR in B cells has been explored, and genes associated with autoimmune diseases are overrepresented in this spectrum,<sup><xref ref-type="bibr" rid="bib36">36</xref></sup> the potential role of VDR in DCs and other myeloid cells has yet to be characterized. For the reasons above, we believe these cells to be priority targets.</p><p>In this study we identify the VDR cistrome in myeloid (monocytes, inflammatory and tolerogenic DCs) immune cells and map it against genetic loci identified as risk factors for autoimmune states. We used chromatin immunoprecipitation and next generation sequencing to identify the VDR-binding sites in monocytes and two types of <italic>in vitro</italic> differentiated DCs: inflammatory (stimulated with interferon gamma, DC1) and tolerogenic (stimulated with interferon beta, DC2). The phenotypes of these cells were demonstrated in an earlier study.<sup><xref ref-type="bibr" rid="bib30">30</xref></sup> Here we show that there are striking similarities in genomic locations of VDR-binding sites among the myeloid cell subsets, but also many which change dramatically with differentiation state. Differences are also seen in the spectrum of transcription factor (TF) recognition sequences co-located with the VDR peaks. Finally, latitude-dependent autoimmune disease (LAD) risk loci are overrepresented in the genomic vicinity of VDR peaks, pointing to a regulatory architecture that might be exploited for therapeutic purposes.</p></sec><sec><title>Results</title><sec><title>Expression of <italic>CYP27B1</italic> and <italic>CYP24A1</italic> in immune cells</title><p>The association of <italic>CYP27B1</italic> and <italic>CYP24A1</italic> with LADs implicates Vit D in their development. To address this notion, we identified the immune cell subsets able to respond to 25D3 on the basis of expression of <italic>CYP27B1</italic> and <italic>VDR</italic>, and in which <italic>CYP24A1</italic> expression was high. Although many cell subsets expressed <italic>VDR</italic>, and so could respond to 1,25D3, only myeloid cells exhibited high expression of <italic>CYP27B1</italic> and <italic>CYP24A1</italic> (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec><title>VDR binding in monocytes, DC1 and DC2</title><p>We then sought the genes regulated by VDR in myeloid cells using VDR ChIP-Seq (chromatin immunoprecipitation coupled with high-throughput deep sequencing) to identify the VDR-binding sites in both unstimulated and calcipotriol (synthetic derivative of 1,25D3&#x02014;used to maximize genomic VDR binding) stimulated monocytes, monocyte-derived inflammatory (DC1) and tolerogenic (DC2) DCs. The canonical Vit D response element (VDRE) motif was highly overrepresented in VDR ChIP-Seq binding peaks in stimulated monocytes (40&#x00025;), DC1 (21&#x00025;) and DC2 (47&#x00025;), <italic>P&#x0003c;</italic>E<sup>&#x02212;100</sup> for all cell types (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Of the nearly 11&#x02009;000 VDR-binding peaks identified across the genome in DC1s, 1317 were shared with DC2s (91&#x00025; of DC2 sites) and 1579 with monocytes (83&#x00025; of monocyte sites) (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). The highly significant overrepresentation of the VDRE motif in the binding peaks and the level of overlap between the cell subset cistromes indicate that the data are of high quality.</p></sec><sec><title>Comparison of VDR binding in other cell types</title><p>There was overlap of the myeloid VDR cistromes with hepatic stellate cells (LX2) and B cells (<xref ref-type="fig" rid="fig3">Figure 3b</xref>), though to a lesser degree than between the myeloid cell subsets. Overlap between each of the myeloid cell subsets with LX2s and B cells were similar. Overlap between the immune cell subsets, B cells and myeloids was greater than with stellate cells.</p></sec><sec><title>Representation of autoimmune disease risk genes in the myeloid VDR cistrome</title><p>Subsequently, we matched the genes identified as VDR binding in myeloid cell subsets with known risk factor single nucleotide polymorphisms for autoimmune disease. Using HOMER,<sup><xref ref-type="bibr" rid="bib37">37</xref></sup> the overrepresentation of autoimmune disease risk factor single nucleotide polymorphisms (from individual GWAS from the NIH GWAS catalog) within 5000&#x02009;bp of VDR-binding peaks was found to be very high (<xref rid="tbl1" ref-type="table">Table 1</xref>). Of the 2293 GWAS on the GWAS catalog, only 15 studies had an excess of single nucleotide polymorphisms from the VDR cistrome at <italic>P&#x0003c;</italic>10<sup>&#x02212;4</sup> (not corrected for multiple testing). Of these 15 studies, 10 were of autoimmune diseases, 9 of the 10 with evidence of latitude affects and serum 25D3 levels on risk. The autoimmune disease GWAS overrepresented included multiple sclerosis (MS), inflammatory bowel disease, rheumatoid arthritis and systemic lupus erythematosus. Four of the enriched GWAS were for conditions affected by cholesterol, which competes with 25D3 for their mutual precursor squalene. The final disease was attention deficit hyperactivity disorder, known to be affected by latitude and Vit D deficiency. A typical example of VDR-binding peak location, effect of calcipotriol on the peak, co-location with other TF motifs and gene expression in the three myeloid subsets for an LAD risk gene is shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>. The MS risk genes that contained VDR-binding peaks and VDRE motifs for each myeloid cell subset examined are shown in <xref rid="tbl2" ref-type="table">Table 2</xref>.</p></sec><sec><title>Autoimmune risk gene TF motifs in VDR peaks</title><p>Genes encoding TFs are overrepresented among MS risk genes.<sup><xref ref-type="bibr" rid="bib38">38</xref></sup> Of the 26 TFs affecting genetic risk of MS, 14 are predominantly expressed in myeloid cells;<sup><xref ref-type="bibr" rid="bib38">38</xref></sup> it is likely they regulate myeloid cell differentiation and/or state. Of these, seven had a VDR ChIP-Seq peak within 5&#x02009;kb of the MS risk single-nucleotide polymorphism closest to the gene, with six having the canonical VDRE motif within the peak (<xref rid="tbl3" ref-type="table">Table 3</xref>, see next section for further detail on binding peaks with and without the VDRE motif).</p><p>Of TF motifs overrepresented in the VDR ChIP-Seq-binding peaks, one MS risk factor, <italic>BATF</italic>, was highly overrepresented; this was seen in DC1s and DC2s at <italic>P&#x0003c;</italic>E<sup>&#x02212;100</sup> but not in monocytes. All the seven MS risk gene TFs containing VDR-binding peaks had BATF recognition motifs co-localized with the peak (genes <italic>NFKB1</italic>, <italic>IRF8</italic> (<xref ref-type="fig" rid="fig4">Figure 4</xref>), <italic>ZMIZ1</italic>, <italic>STAT3</italic>, <italic>STAT4</italic>, <italic>ZNF438</italic>).</p></sec><sec><title>Other TF recognition motifs in VDR-binding peaks with/without the VDRE motif</title><p>We characterized the presence of other TF motifs in all the VDR-binding peaks, those containing the VDRE motif and those without (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S1</xref>). Eight of the TF motifs were for genes expressed predominantly in myeloid cell subsets, although there were some striking differences, pointing to interactions between VDR and these TFs in orchestration of myeloid development. Six TFs were monocyte specific, 16 DC1 specific and 10 DC2 specific. To determine if these different TFs represented particular cellular roles, we investigated if they were overrepresented in curated pathways (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S1</xref>). IL1 (2.6E<sup>&#x02212;6</sup>), IL6 (6.1E<sup>&#x02212;9</sup>) and MIF (9.2E<sup>&#x02212;5</sup>) (not corrected for multiple testing) signaling pathways associated with inflammation were overrepresented in the DC1 motifs, but not significantly overrepresented in the DC2 motifs.</p><p>The absence of canonical VDR motifs in many peaks has been observed in other ChIP-Seq data sets, and implicates tethering of VDR to other TFs (and their target DNA motif).<sup><xref ref-type="bibr" rid="bib39">39</xref>, <xref ref-type="bibr" rid="bib40">40</xref></sup> In each cell type, the TFs overrepresented in the VDR-binding peaks with and without the VDRE motif largely did not overlap. The overlapping TFs were AP-1, SFPI1, JUND for monocyte; BATF, EGR2, HNF4A, RELA and SPI1 for DC1 and CEBPB and SPI1 for DC2.</p></sec><sec><title>The tolerogenic cistrome</title><p>The 121 genes containing VDR-binding peaks in DC2s, but not the DC1s or monocytes, are defined here as the <italic>tolerogenic cistrome</italic> (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S2</xref>). Notably, mRNA expression of PGE synthase, known to modulate tolerance through the PGE2 signaling network,<sup><xref ref-type="bibr" rid="bib41">41</xref></sup> was the only gene (from the 121 defining the tolerogenic cistrome) differentially expressed between the cell subsets based on RNA-Seq data.</p></sec></sec><sec><title>Discussion</title><p>We present evidence that the VDR binds at thousands of sites in the genome of human monocytes and DCs, of which about half have the canonical VDRE motif. Furthermore, we show a higher degree of overlap of VDR-binding sites between myeloid subsets than between myeloids, hepatic stellate cells and B lymphocytes, and that the binding sites can change depending on the myeloid cell differentiation state. The recognition motifs for other TFs at these sites are highly non-random, with an overrepresentation of TFs known to interact with VDR from other studies, and which are known to control immune responses. Also overrepresented within 5&#x02009;kb of these sites are genes associated with LADs, especially with MS. These data indicate that VDR interacts with key TFs in complexes to control the transcriptome and thereby the differentiation state of myeloid cells. Our findings suggest that perturbed VDR binding at autoimmune disease risk gene variants may contribute to the susceptibility to LADs.</p><p>Genes nearest to VDR-binding sites are enriched for immune function and risk of LADs. Since the myeloid cells provide a crucial arm of the immune response, controlling processes such as antigen presentation, removal of cellular debris and other sources of antigen, licensing of T and B cells, controlling the cytokine environment at sites of inflammation (trauma, infection) and in the primary and secondary lymphoid organs, it is not surprising that a large proportion of the genes known to be associated with autoimmune risk are predominantly expressed in myeloid cells.<sup><xref ref-type="bibr" rid="bib42">42</xref></sup> The identification of these genes in this study, together with future evaluation of the effects of the risk genetic variants on VDR and other TF regulation of the risk genes, should enable a more directed understanding of the transcriptomic interactions important in the dysregulation of the immune response that leads to autoimmune disease.</p><p>A number of papers have recently characterized the transcriptome of myeloid subsets, in conjunction with analysis of genetic variation.<sup><xref ref-type="bibr" rid="bib43">43</xref>, <xref ref-type="bibr" rid="bib44">44</xref>, <xref ref-type="bibr" rid="bib45">45</xref></sup> Autoimmune genes were overrepresented in those genes whose expression changed with differentiation, notably on tumor necrosis factor-&#x003b1; stimulation.<sup><xref ref-type="bibr" rid="bib45">45</xref></sup> The enzyme catalyzing activation of 25D3 to 1,25D3, Cyp27B1, is one of the most upregulated with the majority of the forms of monocyte stimulation employed in these studies. It remains to be determined if this results in increased VDR activity and subsequent restoration of homeostasis, or if a more complex form of control of myeloid cells is initiated. Given the complexity of the VDR cistrome in inflammatory as well as tolerogenic DCs, the latter seems more likely.</p><p>The changes in distribution of VDR-binding sites in different myeloid subsets, and the different spectrum of TF motifs overrepresented in these sites, indicate the architecture of myeloid differentiation is heavily influenced by the VDR activity. Specifically, we have compelling evidence that VDR and BATF may share an intersecting genomic circuit that regulates development of DCs. This extends from our previous demonstration that VDR ligands inhibit hepatic stellate activation by TGF&#x003b2;<sub>1</sub> and abrogate liver fibrosis, whereas VDR knockout mice spontaneously develop hepatic fibrosis.<sup><xref ref-type="bibr" rid="bib46">46</xref></sup> Mechanistically, we showed that TGF&#x003b2;<sub>1</sub> signaling causes a redistribution of genome-wide VDR-binding sites, which facilitates VDR binding at SMAD3 profibrotic target genes in these cells. In the presence of VDR ligands, VDR binding to the coregulated genes reduces SMAD3 occupancy at these sites, inhibiting fibrosis. We propose that VDR and BATF may interact in a similar fashion to control monocyte maturation.</p><p>BATF is known to be a core TF in myeloid cell differentiation.<sup><xref ref-type="bibr" rid="bib47">47</xref></sup> The BATF motif was found in 24&#x00025; of VDR-captured sequences for DC1s and 28&#x00025; for DC2s. It is interesting that BATF is relatively highly expressed in DC1s and DC2s, but not monocytes. Since the overrepresentation of BATF sites at VDR peaks occurs only where BATF protein would be present, this is consistent with the BATF protein actually binding to its cognate motif in the VDR-captured sequence. The VDR ChIP-Seq BATF sites were in putative promoter regions of LAD risk genes likely to control the tolerance/inflammatory development of DCs, including <italic>CYP27B1</italic> and <italic>CYP24A1</italic>. The protein encoded by <italic>BATF</italic> is a nuclear basic leucine zipper protein that belongs to the AP-1/ATF superfamily of TFs; BATF knockout mice lack Th17 cells and are resistant to encephalomyelitis, a mouse model of MS.<sup><xref ref-type="bibr" rid="bib47">47</xref></sup> Its absence from murine cells has been shown to perturb the balance of many TFs, which also produce an altered CD8 T-cell phenotype and functional consequences.<sup><xref ref-type="bibr" rid="bib48">48</xref></sup></p><p>In mouse models of autoimmune diseases, including encephalomyelitis, treatment with antigen-specific or generic tolerogenic DCs is remarkably successful.<sup><xref ref-type="bibr" rid="bib32">32</xref></sup> This has led to clinical trials in humans, with promising results, especially with autologous DCs.<sup><xref ref-type="bibr" rid="bib34">34</xref></sup> However, a major limitation is that the functional state of DCs can vary dramatically according to their surrounding cytokine environment or presence of stimulating factors, so that the choice of manipulation needs to be further informed by experimental data, and reliable quality control measurements of manipulation are needed. The importance of Vit D in inducing and maintaining a tolerogenic DC phenotype is well established.<sup><xref ref-type="bibr" rid="bib28">28</xref>, <xref ref-type="bibr" rid="bib35">35</xref></sup> Knowledge of the precise changes to the DC VDR cistrome and subsequent transcriptome, including with the interactions with other TFs such as BATF, and determination of the effects of the LAD risk gene genotypes on these processes, may allow a better understanding of myeloid cell plasticity and thereby utility for therapy. From this study, a set of genes in <italic>cis</italic> with VDR peaks in DC2s but not with DC1s were identified, and of these PGE2 synthase was differentially expressed between the two. This protein promotes the synthesis of PGE2, a ligand for the MS risk factor PTGER4, and a protein known to mediate resistance to encephalomyelitis.<sup><xref ref-type="bibr" rid="bib41">41</xref></sup></p><p>Another translational benefit of a better understanding of VDR function in myeloid cells is that it may provide a more targeted approach to preventing or treating autoimmune disease than simple oral 25D<sub>3</sub> supplementation. Many drugs have been designed to manipulate the Vit D3 pathway.<sup><xref ref-type="bibr" rid="bib49">49</xref></sup> The two main issues affecting the therapeutic use of VDR agonist ligands are increased intestinal calcium absorption leading to hypercalcaemia and loss of activity due to VDR-mediated upregulation of <italic>CYP24A1</italic> leading to ligand catabolism. To overcome this a number of approaches have been adopted, including design of VDR ligands that cause minimal elevation of serum calcium and display relative resistance to Cyp24A1-mediated degradation.<sup><xref ref-type="bibr" rid="bib49">49</xref></sup> Further, giving the ligand in intermittent pulses helps overcome both of these issues. Finally, targeting the VDR agonist to the cell type relevant to the therapeutic effect is a logical approach to therapy, but this necessitates a detailed mechanistic knowledge of the disease process. To date, many clinical trials have been undertaken, but only with the natural endogenous ligand (1,25D<sub>3</sub>) or its immediate precursor (25D<sub>3</sub>), with mixed results.<sup><xref ref-type="bibr" rid="bib50">50</xref></sup></p><p>Our results indicate that VDR regulates transcription from thousands of genomic sites, both with and without canonical VDR recognition motifs, in myeloid cell subsets. There is evidence of interaction with many other immune cell TFs, and of control of myeloid cell differentiation through this interaction, including of genes which are autoimmune disease risk factors. Our data compellingly suggest that VDR and other TFs, notably BATF, combine to regulate myeloid cells, that the balance of cell differentiation, tolerant vs activating, is fundamental to autoimmune disease risk and that manipulation of the process may be therapeutically beneficial.</p></sec><sec><title>Materials and methods</title><sec><title>Cell isolation, differentiation and stimulation</title><p>Peripheral blood mononuclear cells were isolated from EDTA-treated whole blood of healthy controls using Ficoll Paque Plus (GE Healthcare, Uppsala, Sweden). CD14&#x0002b; cells were purified from the peripheral blood mononuclear cells using the Human CD14 Positive Selection Kit (Stem Cell Technologies, Vancouver, BC, Canada) according to the manufacturer's instructions. Cells were plated in X-Vivo15 medium (Lonza, Basel, Switzerland) with 2&#x00025; AB serum in 25&#x02009;cm<sup>2</sup> flasks and treated with three changes of granulocyte macrophage colony-stimulating factor (70&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup>) and IL-4 (10&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup>) over 6 days. On day 6, cells were treated with lipopolysaccharide (250&#x02009;ng&#x02009;ml<sup>&#x02212;1</sup>) and interferon-&#x003b3; (10&#x02009;ngml<sup>&#x02212;1</sup>, for DC1 differentiation) or interferon-&#x003b2; (1000&#x02009;IUml<sup>&#x02212;1</sup>, for DC2 differentiation). Cells cultured without addition of calcipotriol were harvested after 48&#x02009;h. For calcipotriol-treated samples, cells were cultured for 32&#x02009;h before addition of calcipotriol at a final concentration of 100&#x02009;n<sc>m</sc> and cultured for an additional 16&#x02009;h prior to harvest.</p></sec><sec><title>Chromatin immunoprecipitation coupled with high-throughput deep sequencing (ChIP-seq)</title><p>The experimental procedure for ChIP was as previously described.<sup><xref ref-type="bibr" rid="bib51">51</xref></sup> Briefly, after fixation, nuclei from monocyte, DC1 and DC2 cells were isolated, lysed and sheared with a Diagenode Bioruptor (Denville, NJ, USA) to yield DNA fragment sizes of 200&#x02013;1000&#x02009;bp followed by immunoprecipitation using the following antibodies: normal rabbit immunoglobulin G (Santa Cruz, Dallas, TX, USA; sc-2027), VDR (Santa Cruz; sc-1008). ChIP-Seq analysis was performed as previously described.<sup><xref ref-type="bibr" rid="bib51">51</xref></sup> Briefly, short DNA reads generated on an Illumina HiSeq 2000 platform were aligned against the human hg19 reference genome and aligned using the Bowtie2 v2.2.3 aligner with default settings.<sup><xref ref-type="bibr" rid="bib52">52</xref></sup> Only tags that mapped uniquely to the genome were considered for further analysis. Subsequent peak calling and motif analysis were conducted using HOMER (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://homer.salk.edu/homer/">http://homer.salk.edu/homer/</ext-link>).<sup><xref ref-type="bibr" rid="bib37">37</xref></sup> One tag from each unique position was considered to eliminate peaks resulting from clonal amplification of fragments during the ChIP-Seq protocol. Peaks were identified by searching for clusters of tags within a sliding 200&#x02009;bp window, requiring adjacent clusters to be at least 1&#x02009;kb away from each other. The threshold for the number of tags that determine a valid peak was selected for a false discovery rate &#x0003c;0.0001, as empirically determined by repeating the peak finding procedure using randomized tag positions. Peaks are required to have at least fourfold more tags (normalized to total count) than input or immunoglobulin G control samples and fourfold more tags relative to the local background region (10&#x02009;kb) to avoid identifying regions with genomic duplications or nonlocalized binding. Peaks are annotated to gene products by identifying the nearest RefSeq transcriptional start site. Visualization of ChIP-Seq results was achieved by uploading custom tracks onto the University of California, Santa Cruz genome browser.</p></sec><sec><title>RNA-Seq</title><p>We used our previously generated RNAseq data set of <italic>ex vivo</italic> and <italic>in vitro</italic> differentiated immune cell subsets to compare relative gene expression levels across different immune cell populations.<sup><xref ref-type="bibr" rid="bib30">30</xref></sup></p></sec></sec></body><back><ack><p>This work was supported by the Australian NHMRC Project Grant 1049936. DB was the Hunt Family MSRA Senior Research Fellow, now NHMRC Senior Research Fellow. RME is an Investigator of the Howard Hughes Medical Institute (HHMI) at the Salk Institute and March of Dimes Chair in Molecular and Developmental Biology, and is supported by National Institutes of Health (NIH) grants (DK057978, DK090962, HL088093, HL105278 and ES010337), the Glenn Foundation for Medical Research, the Leona M and Harry B Helmsley Charitable Trust (&#x00023;2012-PG-MED002). CL and MD were funded by grants from the National Health and Medical Research Council of Australia Project Grants 632886 and 1043199.</p><p><bold>Author contributions</bold></p><p>DB and CL conceived the study. FS and SC carried out the cell culture, ND the ChIP-Seq experiments, GP the RNA-seq experiments and CL conducted the bioinformatic analysis with support from DB and GP. DB wrote the first draft and prepared figures with GP and CL. All authors contributed to and approved the final document.</p></ack><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies this paper on Genes and Immunity website (http://www.nature.com/gene)</p></fn></fn-group><notes><p>The authors declare no conflict of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal">Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L et al. <article-title>Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis</article-title>. <source>Nature</source><year>2011</year>; <volume>476</volume>: <fpage>214</fpage>&#x02013;219.<pub-id pub-id-type="pmid">21833088</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal">Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C et al. <article-title>Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis</article-title>. <source>Nat Genet</source>
<year>2013</year>; <volume>45</volume>: <fpage>1353</fpage>&#x02013;1360.<pub-id pub-id-type="pmid">24076602</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal">Parkes M, Cortes A, van Heel DA, Brown MA. <article-title>Genetic insights into common pathways and complex relationships among immune-mediated diseases</article-title>. <source>Nat Rev Genet</source>
<year>2013</year>; <volume>14</volume>: <fpage>661</fpage>&#x02013;673.<pub-id pub-id-type="pmid">23917628</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal">Cotsapas C, Hafler DA. <article-title>Immune-mediated disease genetics: the shared basis of pathogenesis</article-title>. <source>Trends Immunol</source>
<year>2013</year>; <volume>34</volume>: <fpage>22</fpage>&#x02013;26.<pub-id pub-id-type="pmid">23031829</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal">Ascherio A, Munger KL, Simon KC. <article-title>Vitamin D and multiple sclerosis</article-title>. <source>Lancet Neurol</source>
<year>2010</year>; <volume>9</volume>: <fpage>599</fpage>&#x02013;612.<pub-id pub-id-type="pmid">20494325</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal">Miller DH, Hammond SR, McLeod JG, Purdie G, Skegg DC. <article-title>Multiple sclerosis in Australia and New Zealand: are the determinants genetic or environmental</article-title>? <source>J Neurol Neurosurg Psychiatry</source>
<year>1990</year>; <volume>53</volume>: <fpage>903</fpage>&#x02013;905.<pub-id pub-id-type="pmid">2266373</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal">Khalili H, Huang ES, Ananthakrishnan AN, Higuchi L, Richter JM, Fuchs CS et al. <article-title>Geographical variation and incidence of inflammatory bowel disease among US women</article-title>. <source>Gut</source>
<year>2012</year>; <volume>61</volume>: <fpage>1686</fpage>&#x02013;1692.<pub-id pub-id-type="pmid">22241842</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal">Vieira VM, Hart JE, Webster TF, Weinberg J, Puett R, Laden F et al. <article-title>Association between residences in U.S. northern latitudes and rheumatoid arthritis: a spatial analysis of the Nurses' Health Study</article-title>. <source>Environ Health Perspect</source>
<year>2010</year>; <volume>118</volume>: <fpage>957</fpage>&#x02013;961.<pub-id pub-id-type="pmid">20338859</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal">Walsh SJ, Gilchrist A. <article-title>Geographical clustering of mortality from systemic lupus erythematosus in the United States: contributions of poverty, Hispanic ethnicity and solar radiation</article-title>. <source>Lupus</source>
<year>2006</year>; <volume>15</volume>: <fpage>662</fpage>&#x02013;670.<pub-id pub-id-type="pmid">17120593</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal">Simpson S Jr, Blizzard L, Otahal P, Van der Mei I, Taylor B. <article-title>Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2011</year>; <volume>82</volume>: <fpage>1132</fpage>&#x02013;1141.<pub-id pub-id-type="pmid">21478203</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal">Berlanga-Taylor AJ, Disanto G, Ebers GC, Ramagopalan SV. <article-title>Vitamin D-gene interactions in multiple sclerosis</article-title>. <source>J Neurol Sci</source>
<year>2011</year>; <volume>311</volume>: <fpage>32</fpage>&#x02013;36.<pub-id pub-id-type="pmid">22000399</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal">Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. <article-title>Association between inflammatory bowel disease and vitamin D deficiency: a systematic review and meta-analysis</article-title>. <source>Inflamm Bowel Dis</source>
<year>2015</year>; <volume>21</volume>: <fpage>2708</fpage>&#x02013;2717.<pub-id pub-id-type="pmid">26348447</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal">Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. <article-title>High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis</article-title>. <source>Neurology</source>
<year>1994</year>; <volume>44</volume>: <fpage>1687</fpage>&#x02013;1692.<pub-id pub-id-type="pmid">7936297</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal">Jorgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, Dahlerup JF. <article-title>Active Crohn's disease is associated with low vitamin D levels</article-title>. <source>J Crohn's Colitis</source>
<year>2013</year>; <volume>7</volume>: <fpage>e407</fpage>&#x02013;e413.<pub-id pub-id-type="pmid">23403039</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal">Tavakkoli A, DiGiacomo D, Green PH, Lebwohl B. <article-title>Vitamin D status and concomitant autoimmunity in celiac disease</article-title>. <source>J Clin Gastroenterol</source>
<year>2013</year>; <volume>47</volume>: <fpage>515</fpage>&#x02013;519.<pub-id pub-id-type="pmid">23328299</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal">Hong Q, Xu J, Xu S, Lian L, Zhang M, Ding C. <article-title>Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford)</source>
<year>2014</year>; <volume>53</volume>: <fpage>1994</fpage>&#x02013;2001.<pub-id pub-id-type="pmid">24907153</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal">Mok CC. <article-title>Vitamin D and systemic lupus erythematosus: an update</article-title>. <source>Expert Rev Clin Immunol</source>
<year>2013</year>; <volume>9</volume>: <fpage>453</fpage>&#x02013;463.<pub-id pub-id-type="pmid">23634739</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal">Bahlo M, Booth DR, Broadley SA, Brown MA, Foote SJ, Griffiths LR et al. <article-title>Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20</article-title>. <source>Nat Genet</source>
<year>2009</year>; <volume>41</volume>: <fpage>824</fpage>&#x02013;U84.<pub-id pub-id-type="pmid">19525955</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal">Bailey R, Cooper JD, Zeitels L, Smyth DJ, Yang JH, Walker NM et al. <article-title>Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes</article-title>. <source>Diabetes</source>
<year>2007</year>; <volume>56</volume>: <fpage>2616</fpage>&#x02013;2621.<pub-id pub-id-type="pmid">17606874</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal">Cotsapas C, Voight BF, Rossin E, Lage K, Neale BM, Wallace C et al. <article-title>Pervasive sharing of genetic effects in autoimmune disease</article-title>. <source>PLoS Genet</source>
<year>2011</year>; <volume>7</volume>: <fpage>e1002254</fpage>.<pub-id pub-id-type="pmid">21852963</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal">Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY et al. <article-title>Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease</article-title>. <source>Nature</source>
<year>2012</year>; <volume>491</volume>: <fpage>119</fpage>&#x02013;124.<pub-id pub-id-type="pmid">23128233</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal">Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al. <article-title>Genetics of rheumatoid arthritis contributes to biology and drug discovery</article-title>. <source>Nature</source>
<year>2014</year>; <volume>506</volume>: <fpage>376</fpage>&#x02013;381.<pub-id pub-id-type="pmid">24390342</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal">Zhernakova A, Stahl EA, Trynka G, Raychaudhuri S, Festen EA, Franke L et al. <article-title>Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci</article-title>. <source>PLoS Genet</source>
<year>2011</year>; <volume>7</volume>: <fpage>e1002004</fpage>.<pub-id pub-id-type="pmid">21383967</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal">Haroon M, Fitzgerald O. <article-title>Vitamin D and its emerging role in immunopathology</article-title>. <source>Clin Rheumatol</source>
<year>2012</year>; <volume>31</volume>: <fpage>199</fpage>&#x02013;202.<pub-id pub-id-type="pmid">22020389</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal">Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. <article-title>Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis</article-title>. <source>JAMA</source>
<year>2006</year>; <volume>296</volume>: <fpage>2832</fpage>&#x02013;2838.<pub-id pub-id-type="pmid">17179460</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal">Smolders J, Thewissen M, Peelen E, Menheere P, Tervaert JW, Damoiseaux J et al. <article-title>Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis</article-title>. <source>PLoS One</source>
<year>2009</year>; <volume>4</volume>: <fpage>e6635</fpage>.<pub-id pub-id-type="pmid">19675671</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal">Adorini L, Penna G. <article-title>Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists</article-title>. <source>Hum Immunol</source>
<year>2009</year>; <volume>70</volume>: <fpage>345</fpage>&#x02013;352.<pub-id pub-id-type="pmid">19405173</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal">Nagy L, Szanto A, Szatmari I, Szeles L. <article-title>Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response</article-title>. <source>Physiol Rev</source>
<year>2012</year>; <volume>92</volume>: <fpage>739</fpage>&#x02013;789.<pub-id pub-id-type="pmid">22535896</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal">Szeles L, Keresztes G, Torocsik D, Balajthy Z, Krenacs L, Poliska S et al. <article-title>1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype</article-title>. <source>J Immunol</source>
<year>2009</year>; <volume>182</volume>: <fpage>2074</fpage>&#x02013;2083.<pub-id pub-id-type="pmid">19201860</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal">Shahijanian F, Parnell GP, McKay FC, Gatt PN, Shojoei M, O'Connor KS et al. <article-title>The CYP27B1 variant associated with an increased risk of autoimmune disease is underexpressed in tolerizing dendritic cells</article-title>. <source>Hum Mol Genet</source>
<year>2014</year>; <volume>23</volume>: <fpage>1425</fpage>&#x02013;1434.<pub-id pub-id-type="pmid">24158849</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal">Liu SM, Xavier R, Good KL, Chtanova T, Newton R, Sisavanh M et al. <article-title>Immune cell transcriptome datasets reveal novel leukocyte subset-specific genes and genes associated with allergic processes</article-title>. <source>J Allergy Clin Immunol</source>
<year>2006</year>; <volume>118</volume>: <fpage>496</fpage>&#x02013;503.<pub-id pub-id-type="pmid">16890777</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal">Van Brussel I, Lee WP, Rombouts M, Nuyts AH, Heylen M, De Winter BY et al. <article-title>Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality</article-title>? <source>Autoimmun Rev</source>
<year>2014</year>; <volume>13</volume>: <fpage>138</fpage>&#x02013;150.<pub-id pub-id-type="pmid">24120737</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal">Mohammad MG, Hassanpour M, Tsai VW, Li H, Ruitenberg MJ, Booth DW et al. <article-title>Dendritic cells and multiple sclerosis: disease, tolerance and therapy</article-title>. <source>Int J Mol Sci</source>
<year>2012</year>; <volume>14</volume>: <fpage>547</fpage>&#x02013;562.<pub-id pub-id-type="pmid">23271370</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal">Thomas R. <article-title>Dendritic cells as targets or therapeutics in rheumatic autoimmune disease</article-title>. <source>Curr Opin Rheumatol</source>
<year>2014</year>; <volume>26</volume>: <fpage>211</fpage>&#x02013;218.<pub-id pub-id-type="pmid">24389864</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal">Pearce EJ, Everts B. <article-title>Dendritic cell metabolism</article-title>. <source>Nat Rev Immunol</source>
<year>2015</year>; <volume>15</volume>: <fpage>18</fpage>&#x02013;29.<pub-id pub-id-type="pmid">25534620</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal">Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A et al. <article-title>A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution</article-title>. <source>Genome Res</source>
<year>2010</year>; <volume>20</volume>: <fpage>1352</fpage>&#x02013;1360.<pub-id pub-id-type="pmid">20736230</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal">Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P et al. <article-title>Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities</article-title>. <source>Mol Cell</source>
<year>2010</year>; <volume>38</volume>: <fpage>576</fpage>&#x02013;589.<pub-id pub-id-type="pmid">20513432</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal">Parnell GP, Gatt PN, Krupa M, Nickles D, McKay FC, Schibeci SD et al. <article-title>The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease</article-title>. <source>Clin Immunol</source>
<year>2014</year>; <volume>151</volume>: <fpage>16</fpage>&#x02013;24.<pub-id pub-id-type="pmid">24495857</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal">Downes M, Liddle C. <article-title>Look who's talking: nuclear receptors in the liver and gastrointestinal tract</article-title>. <source>Cell Metab</source>
<year>2008</year>; <volume>7</volume>: <fpage>195</fpage>&#x02013;199.<pub-id pub-id-type="pmid">18316024</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal">Tuoresmaki P, Vaisanen S, Neme A, Heikkinen S, Carlberg C. <article-title>Patterns of genome-wide VDR locations</article-title>. <source>PLoS One</source>
<year>2014</year>; <volume>9</volume>: <fpage>e96105</fpage>.<pub-id pub-id-type="pmid">24787735</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal">Scott NM, Ng RL, Gorman S, Norval M, Waithman J, Hart PH. <article-title>Prostaglandin E2 imprints a long-lasting effect on dendritic cell progenitors in the bone marrow</article-title>. <source>J Leukoc Biol</source>
<year>2014</year>; <volume>95</volume>: <fpage>225</fpage>&#x02013;232.<pub-id pub-id-type="pmid">23983226</pub-id></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal">Booth DR. <article-title>The clinical implications from the first hundred known MS susceptibility genes</article-title>. <source>Adv Clin Neurosci Rehabil</source>
<year>2014</year>; <volume>14</volume>: <fpage>10</fpage>&#x02013;13.</mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal">Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F et al. <article-title>Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity</article-title>. <source>Science</source>
<year>2014</year>; <volume>345</volume>: <fpage>1251086</fpage>.<pub-id pub-id-type="pmid">25258085</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal">Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I et al. <article-title>Transcriptome-based network analysis reveals a spectrum model of human macrophage activation</article-title>. <source>Immunity</source>
<year>2014</year>; <volume>40</volume>: <fpage>274</fpage>&#x02013;288.<pub-id pub-id-type="pmid">24530056</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal">Lee MN, Ye C, Villani AC, Raj T, Li W, Eisenhaure TM et al. <article-title>Common genetic variants modulate pathogen-sensing responses in human dendritic cells</article-title>. <source>Science</source>
<year>2014</year>; <volume>343</volume>: <fpage>1246980</fpage>.<pub-id pub-id-type="pmid">24604203</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="journal">Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R et al. <article-title>A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response</article-title>. <source>Cell</source>
<year>2013</year>; <volume>153</volume>: <fpage>601</fpage>&#x02013;613.<pub-id pub-id-type="pmid">23622244</pub-id></mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal">Schraml BU, Hildner K, Ise W, Lee WL, Smith WA, Solomon B et al. <article-title>The AP-1 transcription factor Batf controls T(H)17 differentiation</article-title>. <source>Nature</source>
<year>2009</year>; <volume>460</volume>: <fpage>405</fpage>&#x02013;409.<pub-id pub-id-type="pmid">19578362</pub-id></mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal">Kurachi M, Barnitz RA, Yosef N, Odorizzi PM, DiIorio MA, Lemieux ME et al. <article-title>The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8&#x0002b; T cells</article-title>. <source>Nat Immunol</source>
<year>2014</year>; <volume>15</volume>: <fpage>373</fpage>&#x02013;383.<pub-id pub-id-type="pmid">24584090</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal">Schuster I, Bernhardt R. <article-title>Inhibition of cytochromes p450: existing and new promising therapeutic targets</article-title>. <source>Drug Metab Rev</source>
<year>2007</year>; <volume>39</volume>: <fpage>481</fpage>&#x02013;499.<pub-id pub-id-type="pmid">17786634</pub-id></mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal">Munger KL, Ascherio A. <article-title>Prevention and treatment of MS: studying the effects of vitamin D</article-title>. <source>Mult Scler</source>
<year>2011</year>; <volume>17</volume>: <fpage>1405</fpage>&#x02013;1411.<pub-id pub-id-type="pmid">21998006</pub-id></mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="journal">Barish GD, Yu RT, Karunasiri M, Ocampo CB, Dixon J, Benner C et al. <article-title>Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response</article-title>. <source>Genes Dev</source>
<year>2010</year>; <volume>24</volume>: <fpage>2760</fpage>&#x02013;2765.<pub-id pub-id-type="pmid">21106671</pub-id></mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal">Langmead B, Salzberg SL. <article-title>Fast gapped-read alignment with Bowtie 2</article-title>. <source>Nat Methods</source>
<year>2012</year>; <volume>9</volume>: <fpage>357</fpage>&#x02013;359.<pub-id pub-id-type="pmid">22388286</pub-id></mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="journal">Grimes DS, Hindle E, Dyer T. <article-title>Sunlight, cholesterol and coronary heart disease</article-title>. <source>QJM</source>
<year>1996</year>; <volume>89</volume>: <fpage>579</fpage>&#x02013;589.<pub-id pub-id-type="pmid">8935479</pub-id></mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal">Icli A, Aksoy F, Nar G, Kaymaz H, Alpay MF, Nar R et al. <article-title>Increased mean platelet volume in familial hypercholesterolemia</article-title>. <source>Angiology</source>
<year>2015</year>; <volume>67</volume>: <fpage>146</fpage>&#x02013;150.<pub-id pub-id-type="pmid">25859052</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="journal">Cumhur Cure M, Cure E, Yuce S, Yazici T, Karakoyun I, Efe H. <article-title>Mean platelet volume and vitamin D level</article-title>. <source>Ann Lab Med</source>
<year>2014</year>; <volume>34</volume>: <fpage>98</fpage>&#x02013;103.<pub-id pub-id-type="pmid">24624344</pub-id></mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="journal">Arns M, van der Heijden KB, Arnold LE, Kenemans JL. <article-title>Geographic variation in the prevalence of attention-deficit/hyperactivity disorder: the sunny perspective</article-title>. <source>Biol Psychiatry</source>
<year>2013</year>; <volume>74</volume>: <fpage>585</fpage>&#x02013;590.<pub-id pub-id-type="pmid">23523340</pub-id></mixed-citation></ref><ref id="bib57"><mixed-citation publication-type="journal">Humble MB, Gustafsson S, Bejerot S. <article-title>Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric out-patients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis</article-title>. <source>J Steroid Biochem Mol Biol</source>
<year>2010</year>; <volume>121</volume>: <fpage>467</fpage>&#x02013;470.<pub-id pub-id-type="pmid">20214992</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Table 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gene201612x1.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob2"><label>Supplementary Table 2</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gene201612x2.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob3"><label>Supplementary Figure</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gene201612x3.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="xob4"><label>Supplementary Information</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gene201612x4.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>RNA-Seq determined expression of <italic>CYP27B1</italic>, <italic>CYP24A1</italic> and <italic>VDR</italic> in immune cell subsets. <italic>Y</italic>-axis is expression level.<sup><xref ref-type="bibr" rid="bib30">30</xref></sup> Results are from our data, confirming that of others.<sup><xref ref-type="bibr" rid="bib31">31</xref></sup> MD, monocyte derived; mDC, myeloid DC; pDC, plasmacytoid DC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gene201612f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>The vitamin D response element (VDRE) motif is highly enriched in the identified VDR cistromes of DC1, DC2 and monocyte cell subsets. These response elements typically consist of two conserved hexameric half-sites separated by a three nucleotide spacer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gene201612f2"/></fig><fig id="fig3"><label>Figure 3</label><caption><p>Venn diagram of overlapping VDR-binding sites in (<bold>a</bold>) the three myeloid subsets DC1, DC2 and monocyte (CD14) and (<bold>b</bold>) overlap of the myeloid cell VDR-binding sites with the VDR-binding sites of a hepatic stellate cell line (LX2) and a B-lymphocyte cell line. Overlap of DC2 and DC1 was 91&#x00025; of DC2 peaks; monocyte and DC1 was 83&#x00025; of monocyte peaks; DC2 and monocyte was 51&#x00025; of monocyte peaks; LX2 and myeloid was 19&#x00025; of LX2 peaks; myeloid and B-lymph was 14&#x00025; of myeloid peaks; and LX2 and B-lymph was 14&#x00025; of LX2 peaks. In each case, the cell subset with the largest number of identified VDR peaks is used as the reference to compare overlaps.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gene201612f3"/></fig><fig id="fig4"><label>Figure 4</label><caption><p>Visualization of RNA-seq, VDR ChIP-seq and co-localization of VDRE and BATF-binding sites. Total ChIP-seq peaks for each sample normalized to 1.00e7 to allow for comparison of peak heights. &#x0002b;Cal indicates cells treated for 16&#x02009;h with calcitriol. RNA-seq experiment described in Shahijanian <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib30">30</xref></sup> UCSC genome browser and H3K27 Mark ENCODE track used for visualization.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gene201612f4"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Risk genes for latitude-dependent autoimmune diseases are highly overrepresented in the vitamin D receptor cistrome</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Study (GWAS catalog no.)</italic></th><th align="center" valign="top" charoff="50"><italic>Total risk SNPs</italic></th><th align="center" valign="top" charoff="50"><italic>DC1 peaks overlap</italic></th><th align="center" valign="top" charoff="50"><italic>DC1</italic> P-value</th><th align="center" valign="top" charoff="50"><italic>DC2 peaks overlap</italic></th><th align="center" valign="top" charoff="50"><italic>DC2</italic> P-value</th><th align="center" valign="top" charoff="50"><italic>CD14 peaks overlap</italic></th><th align="center" valign="top" charoff="50"><italic>CD14</italic> P-value</th><th align="center" valign="top" charoff="50"><italic>Latitude effect?</italic></th><th align="center" valign="top" charoff="50"><italic>Vit D deficiency?</italic></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Inflammatory bowel disease (23128233)</td><td align="center" valign="top" charoff="50">110</td><td align="center" valign="top" charoff="50">29</td><td align="center" valign="top" charoff="50">4.8E<sup>&#x02212;18</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">Khalili <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib7">7</xref></sup></td><td align="center" valign="top" charoff="50">Del Pinto <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib12">12</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">Ulcerative colitis (21297633)</td><td align="center" valign="top" charoff="50">47</td><td align="center" valign="top" charoff="50">13</td><td align="center" valign="top" charoff="50">3.7E<sup>&#x02212;09</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">2.11E<sup>&#x02212;02</sup></td><td align="center" valign="top" charoff="50">Khalili <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib7">7</xref></sup></td><td align="center" valign="top" charoff="50">Del Pinto <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib12">12</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">Multiple sclerosis (21833088)</td><td align="center" valign="top" charoff="50">81</td><td align="center" valign="top" charoff="50">16</td><td align="center" valign="top" charoff="50">1.2E<sup>&#x02212;08</sup></td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">3.30E<sup>&#x02212;03</sup></td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">6.88E<sup>&#x02212;03</sup></td><td align="center" valign="top" charoff="50">Simpson <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib10">10</xref></sup></td><td align="center" valign="top" charoff="50">Nieves <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib13">13</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">Crohn's disease (21102463)</td><td align="center" valign="top" charoff="50">69</td><td align="center" valign="top" charoff="50">14</td><td align="center" valign="top" charoff="50">6.9E<sup>&#x02212;08</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">2.07E<sup>&#x02212;05</sup></td><td align="center" valign="top" charoff="50">Khalili <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib7">7</xref></sup></td><td align="center" valign="top" charoff="50">J&#x000f8;rgensen <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib14">14</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">HDL cholesterol (20686565)</td><td align="center" valign="top" charoff="50">47</td><td align="center" valign="top" charoff="50">10</td><td align="center" valign="top" charoff="50">3.2E<sup>&#x02212;06</sup></td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">1.28E<sup>&#x02212;02</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">Grimes <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib53">53</xref></sup></td><td align="center" valign="top" charoff="50">NA</td></tr><tr><td align="left" valign="top" charoff="50">Mean platelet volume (22139419)</td><td align="center" valign="top" charoff="50">29</td><td align="center" valign="top" charoff="50">8</td><td align="center" valign="top" charoff="50">3.9E<sup>&#x02212;06</sup></td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">3.82E<sup>&#x02212;06</sup></td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">8.37E<sup>&#x02212;03</sup></td><td align="center" valign="top" charoff="50">Icli <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib54">54</xref></sup></td><td align="center" valign="top" charoff="50">Cumhur Cure <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib55">55</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">Celiac disease (20190752)</td><td align="center" valign="top" charoff="50">40</td><td align="center" valign="top" charoff="50">9</td><td align="center" valign="top" charoff="50">6.2E<sup>&#x02212;06</sup></td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">1.42E<sup>&#x02212;05</sup></td><td align="center" valign="top" charoff="50">3</td><td align="center" valign="top" charoff="50">9.20E<sup>&#x02212;04</sup></td><td align="center" valign="top" charoff="50">NA</td><td align="center" valign="top" charoff="50">Tavakkoli <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib15">15</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">Fibrinogen (23969696)</td><td align="center" valign="top" charoff="50">23</td><td align="center" valign="top" charoff="50">7</td><td align="center" valign="top" charoff="50">7.8E<sup>&#x02212;06</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">Grimes <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib53">53</xref></sup></td><td align="center" valign="top" charoff="50">NA</td></tr><tr><td align="left" valign="top" charoff="50">HDL cholesterol (24097068)</td><td align="center" valign="top" charoff="50">71</td><td align="center" valign="top" charoff="50">11</td><td align="center" valign="top" charoff="50">2.6E<sup>&#x02212;05</sup></td><td align="center" valign="top" charoff="50">2</td><td align="center" valign="top" charoff="50">2.77E<sup>&#x02212;02</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">Grimes <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib53">53</xref></sup></td><td align="center" valign="top" charoff="50">NA</td></tr><tr><td align="left" valign="top" charoff="50">Rheumatoid arthritis (20453842)</td><td align="center" valign="top" charoff="50">28</td><td align="center" valign="top" charoff="50">7</td><td align="center" valign="top" charoff="50">3.2E<sup>&#x02212;05</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">Vieira <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib8">8</xref></sup></td><td align="center" valign="top" charoff="50">Hong <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib16">16</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">ADHD (23527680)</td><td align="center" valign="top" charoff="50">21</td><td align="center" valign="top" charoff="50">6</td><td align="center" valign="top" charoff="50">5.3E<sup>&#x02212;05</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">Arns <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib56">56</xref></sup></td><td align="center" valign="top" charoff="50">Humble <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib57">57</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">Multiple sclerosis (19525955)</td><td align="center" valign="top" charoff="50">8</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">8.3E<sup>&#x02212;05</sup></td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2.87E<sup>&#x02212;02</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">Simpson <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib10">10</xref></sup></td><td align="center" valign="top" charoff="50">Nieves <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib13">13</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">Crohn's disease (23850713)</td><td align="center" valign="top" charoff="50">8</td><td align="center" valign="top" charoff="50">4</td><td align="center" valign="top" charoff="50">8.3E<sup>&#x02212;05</sup></td><td align="center" valign="top" charoff="50">1</td><td align="center" valign="top" charoff="50">2.87E<sup>&#x02212;02</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">Khalili <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib7">7</xref></sup></td><td align="center" valign="top" charoff="50">J&#x000f8;rgensen <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib14">14</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">Multiple sclerosis (19525953)</td><td align="center" valign="top" charoff="50">15</td><td align="center" valign="top" charoff="50">5</td><td align="center" valign="top" charoff="50">1.0E<sup>&#x02212;04</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">Simpson <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib10">10</xref></sup></td><td align="center" valign="top" charoff="50">Nieves <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib13">13</xref></sup></td></tr><tr><td align="left" valign="top" charoff="50">Systemic lupus erythematosus (23273568)</td><td align="center" valign="top" charoff="50">34</td><td align="center" valign="top" charoff="50">7</td><td align="center" valign="top" charoff="50">1.2E<sup>&#x02212;04</sup></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">NS</td><td align="center" valign="top" charoff="50">Walsh and Gilchrist<sup><xref ref-type="bibr" rid="bib9">9</xref></sup></td><td align="center" valign="top" charoff="50">Mok<sup><xref ref-type="bibr" rid="bib17">17</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: ADHD, attention deficit hyperactivity disorder; GWAS, genome-wide association study; HDL, high-density lipoprotein; NA, no supporting evidence; NS, no statistically significant enrichment at <italic>P</italic>=0.05; Peaks Overlap; number of VDR-binding peaks identified where a GWAS risk SNP is located within 5000&#x02009;bp.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>MS risk genes with VDR peaks and VDRE motifs</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>MS risk genes</italic></th><th align="center" valign="top" charoff="50"><italic>Myeloid cell subsets</italic></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>CARD11</italic>, <italic>CYP24A1</italic>, <italic>FOXP1</italic>, <italic>MAPK1,</italic>
<italic>MIR1208</italic>, <italic>SLC44A2,</italic>
<italic>SLC9A8</italic>, <italic>TNFAIP3</italic>, <italic>ZMIZ1</italic>, <italic>ZFP36L1</italic></td><td align="center" valign="top" charoff="50">CD14, DC1, DC2</td></tr><tr><td align="left" valign="top" charoff="50"><italic>CD86</italic>, <italic>ZFP36L2</italic></td><td align="center" valign="top" charoff="50">CD14, DC1</td></tr><tr><td align="left" valign="top" charoff="50"><italic>EOMES</italic>, <italic>PTGER4</italic>, <italic>RGS1</italic>, <italic>RMI2</italic>, <italic>CD69</italic></td><td align="center" valign="top" charoff="50">DC1, DC2</td></tr><tr><td align="left" valign="top" charoff="50"><italic>CD40</italic>, <italic>CD83</italic>, <italic>ELMO1, IQGAP1, IRF8, JDP2, MAF, MALT1, PLEK, SATB1, STAT3, TRAF3, VMP1, IL7R, CTSH</italic></td><td align="center" valign="top" charoff="50">DC1</td></tr><tr><td align="left" valign="top" charoff="50"><italic>IFI30</italic></td><td align="center" valign="top" charoff="50">DC2</td></tr></tbody></table></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Evidence for MS risk myeloid transcription factors regulated by VDR</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>MS risk myeloid transcription factor</italic></th><th align="center" valign="top" charoff="50"><italic>Myeloid cell in which expressed</italic></th><th colspan="2" align="center" valign="top" charoff="50"><italic>VDR</italic><hr/></th><th align="center" valign="top" charoff="50"><italic>BATF</italic></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50"><italic>VDR Peak</italic></th><th align="center" valign="top" charoff="50"><italic>VDR motif</italic></th><th align="center" valign="top" charoff="50"><italic>BATF motif</italic></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>BCL10</italic></td><td align="center" valign="top" charoff="50">CD14</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50"><italic>BATF</italic></td><td align="center" valign="top" charoff="50">DC1, DC2</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50"><italic>HHEX1</italic></td><td align="center" valign="top" charoff="50">CD14</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50"><italic>IRF8</italic></td><td align="center" valign="top" charoff="50">All</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50"><italic>MAF</italic></td><td align="center" valign="top" charoff="50">CD14, DC1</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50"><italic>NFKB1</italic></td><td align="center" valign="top" charoff="50">DC2</td><td align="center" valign="top" charoff="50">Yes (DC1 only)</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50"><italic>POU5F1B</italic></td><td align="center" valign="top" charoff="50">DC1, DC2</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50"><italic>STAT3</italic></td><td align="center" valign="top" charoff="50">DC1, DC2</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50"><italic>STAT4</italic></td><td align="center" valign="top" charoff="50">DC2</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50"><italic>ZBTB46</italic></td><td align="center" valign="top" charoff="50">CD14, DC2</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50"><italic>ZFP36L1</italic></td><td align="center" valign="top" charoff="50">CD14</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50"><italic>ZNF438</italic></td><td align="center" valign="top" charoff="50">All</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50"><italic>ZMIZ1</italic></td><td align="center" valign="top" charoff="50">CD14, DC1</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td><td align="center" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50"><italic>ZFP36L2</italic></td><td align="center" valign="top" charoff="50">All</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td><td align="center" valign="top" charoff="50">No</td></tr></tbody></table></table-wrap></floats-group></article>